DUBLIN - Wednesday, November 16th 2011 [ME NewsWire]
Fourth-quarter net sales up 15%; Medical Devices sales up 18%
Fourth-quarter diluted GAAP earnings per share from continuing operations were $0.93; excluding specified items, adjusted diluted earnings per share from continuing operations were $1.08, up 29%
Fiscal 2011 diluted GAAP earnings per share from continuing operations were $3.79; excluding specified items, adjusted diluted earnings per share from continuing operations were $3.97, up 17%
(BUSINESS WIRE)-- Covidien plc (NYSE: COV) today reported results for the fourth quarter of fiscal 2011 (July - September 2011). Net sales of $3.08 billion increased 15% from the $2.67 billion reported in the fourth quarter a year ago. The quarterly sales growth rate benefited from foreign exchange rate movement, which added about four percentage points, and the inclusion of an extra selling week in the fourth quarter of 2011, which added approximately seven to eight percentage points.
Fourth-quarter 2011 gross margin of 56.5% rose 1.6 percentage points from the 54.9% of the prior-year period. On an adjusted basis, excluding the specified items shown on the attached quarterly Non-GAAP reconciliation table, fourth-quarter 2011 gross margin of 56.7% was 0.5 percentage points above that of a year ago. This improvement reflected positive mix in all three business segments, benefits from our restructuring programs and favorable foreign exchange.
Selling, general and administrative (SG&A) expenses for the fourth quarter of 2011 were somewhat above those of the comparable quarter of the year before, primarily due to expenses related to prior year acquisitions and the impact of foreign exchange rate movement. Research and Development (R&D) expense in the fourth quarter climbed 33% and represented 5.4% of net sales, versus 4.7% of sales in the year-ago period.
In the fourth quarter of 2011, the Company reported operating income of $596 million, versus $443 million in the same quarter the year before. Fourth-quarter 2011 adjusted operating income, excluding the specified items, was $685 million, compared with $547 million in the previous year. Fourth-quarter 2011 adjusted operating income, excluding the specified items, represented 22.3% of sales, versus 20.5% in the year-ago period.
The fourth-quarter 2011 effective tax rate was 19.7%, versus a tax benefit in the fourth quarter of 2010. The fourth-quarter 2011 adjusted tax rate, excluding specified items, was 18.2%, versus 15.3% in the fourth quarter a year ago.
Diluted GAAP earnings per share from continuing operations were $0.93 in the fourth quarter of 2011, versus $0.77 per share in the comparable quarter last year. Fourth-quarter 2011 adjusted diluted earnings per share, excluding specified items, were $1.08, versus $0.84 a year ago, a 29% increase.
For fiscal 2011, net sales of $11.57 billion were 11% above the $10.43 billion in the previous year, with favorable foreign exchange increasing the sales growth rate by approximately three percentage points. The addition of an extra selling week in fiscal 2011 also added approximately two percentage points to the sales growth rate.
The Company reported operating income of $2.38 billion in fiscal 2011, versus $2.06 billion a year earlier. Fiscal 2011 adjusted operating income, excluding the specified items shown on the attached Non-GAAP reconciliation table, was $2.57 billion, versus $2.26 billion in the previous year. Fiscal 2011 adjusted operating income, excluding specified items, represented 22.2% of sales, versus 21.7% a year ago.
The effective tax rate was 15.0% for fiscal 2011, versus an effective tax rate of 18.8% in fiscal 2010. Excluding the specified items, the adjusted tax rate for fiscal 2011 was 18.3%, versus 19.5% in fiscal 2010.
For fiscal 2011, diluted GAAP earnings per share from continuing operations were $3.79, versus $3.10 for fiscal 2010. Excluding the specified items, adjusted diluted earnings per share from continuing operations were $3.97, versus $3.38 the year before, a 17% gain.
“We delivered strong fourth-quarter and fiscal 2011 results,” said José E. Almeida, President and CEO. “This performance was aided by successful new product launches, market share gains in several key categories and exceptional commercial execution. We significantly increased R&D spending, made other important growth-driving investments and again generated strong cash flow.
“Looking to 2012, we remain comfortable with the sales and operating margin guidance we issued in September,” Mr. Almeida said. “Although the market environment continues to be challenging, our expectations for the operational growth of our business have not changed. We are confident that our robust new products pipeline, skilled workforce and strategic investments in emerging markets will drive positive operational results in 2012 and beyond.”
BUSINESS SEGMENT RESULTS
Medical Devicessales of $2.09 billion in the fourth quarter rose 18% from the $1.77 billion in the comparable quarter of last year. Operational growth was 12%, driven by acquisitions, new products and greater volume. Operationally, fourth-quarter sales in Endomechanical were above those of the prior year, paced by a good increase for stapling products, led by our innovative Tri-Staple™ reloads. In Soft Tissue Repair, sales growth slowed, as higher sales of sutures were partially offset by a decline for mesh, fixation and biosurgery products. The Energy double-digit quarterly sales gain was again due to a sharp rise in sales of vessel sealing products, coupled with a good performance for electrosurgery. In Oximetry & Monitoring, monitor sales registered a very strong advance, and sensor sales were well above those of a year ago. In Airway & Ventilation, operational sales were virtually unchanged, as higher sales of airway products were countered by lower ventilator sales. Vascular sales climbed at a strong double-digit pace, reflecting new products, a full quarter of neurovascular and peripheral vascular products and, to a lesser extent, double-digit growth for venous insufficiency products.
For fiscal 2011, Medical Devices sales rose 17% to $7.83 billion from $6.72 billion in the prior year. Favorable foreign exchange contributed approximately four percentage points to the increase.
Pharmaceuticalssales of $507 million in the fourth quarter were up 9% from last year’s fourth-quarter sales of $465 million. Foreign exchange rate movement added approximately three percentage points to the fourth-quarter sales change. The increase was fueled by exceptional gains for Specialty Pharmaceuticals, as generic sales climbed at a strong double-digit pace, reflecting the launch of the fentanyl patch, growth for fentanyl lozenge and a continuation of the stabilization in generic pricing seen over the last several quarters. In addition, branded products, including PENNSAID® and EXALGO®, posted sales that were well above those of the year-ago period. Sales of Radiopharmaceuticals were ahead of those of the prior year, as higher generator sales more than countered lower sales of thallium. Sales of Active Pharmaceutical Ingredients advanced from the year-ago level, due primarily to increased sales of acetaminophen. Fourth-quarter sales of Contrast Products were well below those of the year before, largely reflecting difficult comparisons due to customer order patterns.
For fiscal 2011, Pharmaceuticals sales declined 1% to $1.97 billion from $1.99 billion a year ago. The decrease was primarily attributable to the divestiture of the U.S. nuclear pharmacies business in fiscal 2010.
Medical Suppliesfourth-quarter sales of $481 million rose 11% from the $432 million reported in the comparable quarter of the previous year, spurred by higher sales of Nursing Care and Medical Surgical products. The growth in Nursing Care was led by incontinence and enteral feeding products, while the Medical Surgical gain reflected increased sales of the new Kendall™ DL disposable lead wires.
For fiscal 2011, sales of Medical Supplies, at $1.78 billion, were up 3% from last year’s $1.72 billion.
In the fourth quarter of 2011, Covidien purchased approximately 11.7 million ordinary shares under its previously announced share buyback programs.
For fiscal 2011, free cash flow (net cash provided by continuing operating activities less capital expenditures) was approximately $1.7 billion.
FISCAL 2012 OUTLOOK
Covidien has updated its fiscal 2012 tax rate guidance. The Company now expects that the effective tax rate for 2012 will be in the 17% to 18% range, including foreign exchange at current rates and excluding the impact of one-time items. There are no other changes to Covidien’s previously issued 2012 guidance, which follows. Sales in fiscal 2012 are expected to be up 3% to 5%, including foreign exchange at current rates. Net sales are expected to be up 4% to 7% versus 2011 in the Medical Devices segment and up 2% to up 5% in Pharmaceuticals. For the Medical Supplies segment, sales are expected to be about flat. Including foreign exchange at current rates and excluding the impact of one-time items, the operating margin is expected to be in the 22% to 23% range and free cash flow is expected to exceed $1.9 billion.
ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2011 revenue of $11.6 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit www.covidien.comto learn more about our business.
CONFERENCE CALL AND WEBCAST
The Company will hold a conference call for investors today, beginning at 8:30 a.m. ET. This call can be accessed three ways:
At Covidien’s website: http://investor.covidien.com
By telephone: For both “listen-only” participants and those participants who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 866-831-6291. For participants outside the U.S., the dial-in number is 617-213-8860. The access code for all callers is 62952369.
Through an audio replay: A replay of the conference call will be available beginning at 11:30 a.m. on November 15, 2011, and ending at 5:00 p.m. on November 22, 2011. The dial-in number for U.S. participants is 888-286-8010. For participants outside the U.S., the replay dial-in number is 617-801-6888. The replay access code for all callers is 60494415.
NON-GAAP FINANCIAL MEASURES
This press release contains financial measures, including operational growth, adjusted gross margin, adjusted operating income, adjusted earnings per share, adjusted operating margin and free cash flow, which are considered “non-GAAP” financial measures under applicable Securities & Exchange Commission rules and regulations.
These non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with generally accepted accounting principles. The Company’s definition of these non-GAAP measures may differ from similarly titled measures used by others. The Company defines free cash flow as net cash provided by continuing operating activities less capital expenditures.
The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of Covidien’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Covidien's business.
Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.
To view the full report and tables please click here.
Contacts
Covidien plc
Eric Kraus, 508-261-8305
Senior Vice President
Corporate Communications
eric.kraus@covidien.com
Bruce Farmer, 508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
Todd Carpenter, 508-452-4363
Director
Investor Relations
todd.carpenter@covidien.com
No comments:
Post a Comment